Mucinex

(Guaifenesin)

ApprovedSmall molecule

AAultman Health Foundation

Mucinex is one of 163 small molecule programs targeting Respiratory tract infection. It is currently in Approved.

Indications

Total Trials

Active Trials

162

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

SinusitisActive, not recruiting

RhinitisActive, not recruiting

PneumoniaActive, not recruiting

Acute BronchitisActive, not recruiting

Back PainActive, not recruiting

Respiratory Tract InfectionPreclinical

Active, not recruiting

SinusitisApproved

Active, not recruiting

RhinitisPhase 2

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

Acute BronchitisPreclinical

Active, not recruiting

Back PainPreclinical

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Mucinex

AAultman Health Foundation

Approved

1 2

Jakafi

Incyte

Preclinical

1 3

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 5

Advil

KKenvue Brands

Preclinical

2 6

Aciphex

Akero Therapeutics

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Tagamet

DDT MedTech, LLC

Preclinical

1 9

Alka-Seltzer

AAbbott

Preclinical

1 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory tract infection2 trials

Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections

Completed· Pfizer logo

Pfizer·N/A·NCT01062256·265 enrolled

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

Completed·RReckitt Benckiser LLC·Phase 2/3·NCT01537081·2,810 enrolled

Back pain1 trial

Exploratory Efficacy Study of Guaifenesin in Upper Back Pain

Completed· GSK logo

GSK·N/A·NCT01562548·78 enrolled

Rhinitis1 trial

The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study

Completed·VVirginia Commonwealth University·Phase 2·NCT01364467·30 enrolled

Acute bronchitis1 trial

A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis

Completed· Roche logo

Roche··NCT02879981·51 enrolled

Infections1 trial

Preventing Frequent Sinus Infections in HIV-Infected Patients

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000752

7 more indications

Ovulation Induction1 trial

Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction

Completed·YYuzuncu Yil University·N/A·NCT07398924·90 enrolled

Sinusitis1 trial

Treatment of Acute Sinusitis

Completed·WWashington University School of Medicine·Phase 4·NCT00377403·172 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

Completed·RReckitt Benckiser LLC·Phase 4·NCT01202279·1,179 enrolled

ALS1 trial

A Non-Interventional Safety Study of Balsamic Bactrim

Completed· Roche logo

Roche··NCT02902640·52 enrolled

Pneumonia1 trial

Effectiveness Study of Integrative Treatment for Pediatric Pneumonia

Completed·LLiaoning University of Traditional Chinese Medicine·N/A·NCT02069665·451 enrolled

Pediatric Patients1 trial

Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin

Unknown status·AAzidus Brasil·Phase 3·NCT01119534·270 enrolled

Unspecified1 trial

Mucinex Exploratory Cold Study

Completed·RReckitt Benckiser LLC·Phase 2·NCT01046136·378 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 18, 2002

MUCINEX

NDA NDA021282

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Guaifenesin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Guaifenesin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Guaifenesin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021282). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Aultman Health Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAultman Health Foundation

Mucinex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory tract infection2 trials

Back pain1 trial

Rhinitis1 trial

Acute bronchitis1 trial

Infections1 trial

Ovulation Induction1 trial

Sinusitis1 trial

Safety and Efficacy1 trial

ALS1 trial

Pneumonia1 trial

Pediatric Patients1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News